Potential drug candidate for slowing Lou Gehrig’s disease progression identified
October 20th, 2009 - 5:02 pm ICT by ANIWashington, Oct 20 (ANI): A chemical cousin of a drug currently used to treat sepsis has been found to drastically reduce the spread of amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease.
The researchers focussed their study on the use of a form of an enzyme known as activated protein C, or APC, to slow the cell death that occurs in ALS.
They could successfully extend the lifespan of mice with an aggressive form of the disease significantly, by about 25 percent.
The compound also extended the length of time that the mice were able to function well despite showing some symptoms of the disease, and it reduced the pace of muscle wasting that is a hallmark of ALS.
The research involved mice with a mutation in a gene known as superoxide dismutase 1 (SOD1), which plays an important role keeping cells safe from damaging molecules known as free radicals.
While the cause of most cases of ALS is unknown, scientists do know that SOD1 plays a role in approximately 3 or 4 percent of cases - providing an opportunity to study the disease’s initial steps, which occur long before key nerve cells appear sick or die.
In addition, recent studies have suggested that the accumulation of mutant forms of SOD1 is linked to most sporadic cases of ALS.
The team has shown that APC dramatically lessens the activity of the SOD1 mutation.
This protects neurons that are under assault by blocking the synthesis of aberrant forms of the molecule in motor neurons and other cells in the spinal cord.
In addition to reduced SOD1 activity, the flow of dangerous byproducts of hemoglobin into the spinal cord was eliminated by APC, saving neurons.
The study appears in Journal of Clinical Investigation. (ANI)
- Mysterious cells may play role in Lou Gehrig's disease - Nov 18, 2010
- Aging-related protein holds breast cancer clues - Jan 28, 2011
- Transplanted stem cells form proper brain connections in newborn mice - Jan 20, 2010
- Single gene acts as 'master organizer' of motor neurons in spinal cord - Sep 09, 2010
- Blue-green algae used for treating Lou Gehrig's disease in mice model - Dec 22, 2010
- Leaky blood vessels may play key role in Lou Gehrig's progression - Apr 08, 2008
- Loss of key protein contributes to neuron loss in ALS - Mar 05, 2011
- Potential therapeutic target for Parkinson's, Alzheimer's identified - Mar 12, 2011
- Fatal lung vascular disease 'caused by silencing of genes' - Jun 08, 2010
- Scientists shed light on genetics of Lou Gehrig's disease progression - Jun 02, 2008
- Lead paradox could lead to new therapy for Lou Gehrig's disease - Dec 01, 2009
- Stem cells can fix damaged spinal cord tissue - Oct 09, 2010
- Better treatment for spinal injuries could be on its way - Nov 23, 2010
- Can reversal of ageing help save our muscles? - Feb 13, 2010
- Air pollutants lead to age-related muscle decline - Sep 23, 2009
Tags: activated protein c, amyotrophic lateral sclerosis als, byproducts, cell death, chemical cousin, disease progression, drug candidate, free radicals, gehrig s disease, hemoglobin, initial steps, journal of clinical investigation, lateral sclerosis, lou gehrig, motor neurons, muscle wasting, nerve cells, sepsis, sod1, sporadic cases